184 related articles for article (PubMed ID: 35285018)
21. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
Pashayan N; Morris S; Gilbert FJ; Pharoah PDP
JAMA Oncol; 2018 Nov; 4(11):1504-1510. PubMed ID: 29978189
[TBL] [Abstract][Full Text] [Related]
22. A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening.
Koleva-Kolarova RG; Daszczuk AM; de Jonge C; Abu Hantash MK; Zhan ZZ; Postema EJ; Feenstra TL; Pijnappel RM; Greuter MJW; de Bock GH
Maturitas; 2018 Mar; 109():81-88. PubMed ID: 29452787
[TBL] [Abstract][Full Text] [Related]
23. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore.
Wong JZY; Chai JH; Yeoh YS; Mohamed Riza NK; Liu J; Teo YY; Wee HL; Hartman M
BMC Health Serv Res; 2021 Apr; 21(1):379. PubMed ID: 33892705
[TBL] [Abstract][Full Text] [Related]
25. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.
Schiller-Fruehwirth I; Jahn B; Einzinger P; Zauner G; Urach C; Siebert U
Value Health; 2017 Sep; 20(8):1048-1057. PubMed ID: 28964436
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of abbreviated-protocol MRI screening for women with mammographically dense breasts in a national breast cancer screening program.
Wang J; Greuter MJW; Vermeulen KM; Brokken FB; Dorrius MD; Lu W; de Bock GH
Breast; 2022 Feb; 61():58-65. PubMed ID: 34915447
[TBL] [Abstract][Full Text] [Related]
27. Retrospective cost-effectiveness analysis of screening mammography.
Stout NK; Rosenberg MA; Trentham-Dietz A; Smith MA; Robinson SM; Fryback DG
J Natl Cancer Inst; 2006 Jun; 98(11):774-82. PubMed ID: 16757702
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
BMC Health Serv Res; 2009 Jan; 9():9. PubMed ID: 19144138
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States.
Lowry KP; Trentham-Dietz A; Schechter CB; Alagoz O; Barlow WE; Burnside ES; Conant EF; Hampton JM; Huang H; Kerlikowske K; Lee SJ; Miglioretti DL; Sprague BL; Tosteson ANA; Yaffe MJ; Stout NK
J Natl Cancer Inst; 2020 Jun; 112(6):582-589. PubMed ID: 31503283
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.
Pataky R; Ismail Z; Coldman AJ; Elwood M; Gelmon K; Hedden L; Hislop G; Kan L; McCoy B; Olivotto IA; Peacock S
J Med Screen; 2014 Dec; 21(4):180-8. PubMed ID: 25186116
[TBL] [Abstract][Full Text] [Related]
31. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
Mandelblatt JS; Stout NK; Schechter CB; van den Broek JJ; Miglioretti DL; Krapcho M; Trentham-Dietz A; Munoz D; Lee SJ; Berry DA; van Ravesteyn NT; Alagoz O; Kerlikowske K; Tosteson AN; Near AM; Hoeffken A; Chang Y; Heijnsdijk EA; Chisholm G; Huang X; Huang H; Ergun MA; Gangnon R; Sprague BL; Plevritis S; Feuer E; de Koning HJ; Cronin KA
Ann Intern Med; 2016 Feb; 164(4):215-25. PubMed ID: 26756606
[TBL] [Abstract][Full Text] [Related]
32. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
[TBL] [Abstract][Full Text] [Related]
33. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.
Stout NK; Lee SJ; Schechter CB; Kerlikowske K; Alagoz O; Berry D; Buist DS; Cevik M; Chisholm G; de Koning HJ; Huang H; Hubbard RA; Miglioretti DL; Munsell MF; Trentham-Dietz A; van Ravesteyn NT; Tosteson AN; Mandelblatt JS
J Natl Cancer Inst; 2014 Jun; 106(6):dju092. PubMed ID: 24872543
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the Benefits and Cost-Effectiveness of Population-Based Breast Cancer Screening in Urban China: A Model-Based Analysis.
Wang J; Greuter MJW; Zheng S; van Veldhuizen DWA; Vermeulen KM; Wang Y; Lu W; de Bock GH
Int J Health Policy Manag; 2022 Sep; 11(9):1658-1667. PubMed ID: 34273933
[TBL] [Abstract][Full Text] [Related]
35. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
[TBL] [Abstract][Full Text] [Related]
36. Economic potential of abbreviated breast MRI for screening women with dense breast tissue for breast cancer.
Tollens F; Baltzer PAT; Dietzel M; Schnitzer ML; Schwarze V; Kunz WG; Rink J; Rübenthaler J; Froelich MF; Schönberg SO; Kaiser CG
Eur Radiol; 2022 Nov; 32(11):7409-7419. PubMed ID: 35482122
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of adding tomosynthesis to mammography-based breast cancer screening: an economic analysis.
Cressman S; Mar C; Sam J; Kan L; Lohrisch C; Spinelli JJ
CMAJ Open; 2021; 9(2):E443-E450. PubMed ID: 33888549
[TBL] [Abstract][Full Text] [Related]
38. Insights Into Breast Cancer Screening: A Computer Simulation of Two Contemporary Screening Strategies.
Carter KJ; Castro F; Morcos RN
AJR Am J Roentgenol; 2018 Mar; 210(3):564-571. PubMed ID: 29323554
[TBL] [Abstract][Full Text] [Related]
39. Program-specific cost-effectiveness analysis: breast cancer screening policies for a safety-net program.
Melnikow J; Tancredi DJ; Yang Z; Ritley D; Jiang Y; Slee C; Popova S; Rylett P; Knutson K; Smalley S
Value Health; 2013; 16(6):932-41. PubMed ID: 24041343
[TBL] [Abstract][Full Text] [Related]
40. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
